Clinical Trial: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473726) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors' on March 11.

Brief Summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.

Study Start Date: May 17

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Solid Tumors

Intervention: DRUG: HLX48

EGFR/c-MET Bispecific Antibody-Drug Conjugate

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Henlius Biotech

Published by HT Digital Content Services wit...